MARTINS TIMOTHY J.,FOWLER KERRY W.,ODINGO JOSHUA,KESICKI EDWARD A.,OLIVER AMY,BURGESS LAURENCE E.,GAUDINO JOHN J.,JONES ZACHARY S.,NEWHOUSE BRADLEY J.,SCHLACHTER STEPHEN,GAUD
申请号：
SK9172002
公开号：
SK287964B6
申请日:
2000.11.28
申请国别(地区):
SK
年份:
2012
代理人:
摘要：
There are described pyrrolidine compounds having the structural formula (II), where the meaning of substituents is disclosed in the description, that are potent and selective inhibitors of cyclic adenosine 3', 5'-monophosphate specific phosphodiesterase (cAMP specific PDE) especially PDE4. Further, there are described pharmaceutical preparations containing these compounds as well as use of the compounds as therapeutic preparations, for example in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators. Use of these compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.There are described pyrrolidine compounds having the structural formula (II), where the meaning of substituents is disclosed in the description, that are potent and selective inhibitors of cyclic adenosine 3', 5'-monophosphate specific phosphodiesterase (cAMP specific PDE) especially PDE4. Further, there are described pharmaceutical preparations containing these compounds as well as use of the compounds as therapeutic preparations, for example in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators. Use of these compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
